MAPT and Alzheimer disease: The current gold standard biomarkers for AD in the CSF, such as tau, phosphorylated tau (p-tau), and Aβ 1–42, require invasive lumbar punctures, making them less suitable for high throughput screening or patient follow-up (Blennow and Hampel, 2003).